Clinical trials: B7H3
Small Cell Lung Cancer Extensive Stage
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT06954246
- Testing
- MHB088C for Injection, Topotecan, Irinotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in…
- Trial name
- NCT05323201
- Testing
- fhB7H3.CAR-Ts, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
The BeeHive study is an investigator-initiated, single center, open-label phase II clinical trial that is designed to conduct a comprehensive multiomic biomarker evaluation across two single-arm cohorts to elucidate mechanisms of…
- Trial name
- BeeHive (NCT07408063)
- Testing
- GSK5764227, Dostarlimab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Pediatric Solid Tumor, Germ Cell Tumor
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT04483778
- Testing
- second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Seattle Children's Hospital
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
- Trial name
- CMD03DIPG (NCT06221553)
- Testing
- B7H3 specific CAR T cell with IL-7Ra signaling domain
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Chulalongkorn University
Solid Tumor, Meningeal Metastasis
Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors
This is an open, single-arm, single-center, interventional clinical study. It is planned to enroll 3-6 patients with meningeal metastases from B7H3+ solid tumors and to explore, on a small scale, the efficacy of local injection…
- Trial name
- NCT06592092
- Testing
- QH104 Cell injection
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ovarian Cancer
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe…
- Trial name
- NCT07593092
- Testing
- XmAb541, XmAb808
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- Xencor, Inc.
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- HS-20117 (NCT06621563)
- Testing
- HS-20117 combined HS-20093, HS-20117 combined Platinum-containing chemotherapy, HS-20117 combined HS-20093 and 5-FU
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Hansoh BioMedical R&D Company
Recurrent Medulloblastoma, Refractory Medulloblastoma
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
- Conditions
- Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
- Trial name
- NCT07698899
- Testing
- 25 mCi 177Lu- DTPA-omburtamab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Hepatocellular Carcinoma (HCC)
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
This study is a prospective, single-arm, open, single-center clinical trial initiated by the investigator. The principal investigators are professors Shen Feng and Zhang Xiaofeng from The Third Affiliated Hospital of Navy…
- Trial name
- NCT06902389
- Testing
- Super Hi-TCR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Refractory Glioblastoma, Recurrent Glioblastoma
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
This study is an investigator-initiated, open-label Phase I clinical trial designed to evaluate the safety and efficacy of EPC-003 fully human anti-B7H3/IL13Ra2 armored Chimeric Antigen Receptor T-Cell Therapy (CAR-T) cell…
- Trial name
- NCT07193628
- Testing
- EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1), EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2), EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3)
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
This study is a single-arm, open, exploratory clinical study to evaluate the safety and efficacy of EGFR/B7H3 CAR-T in patients with EGFR/ B7H3-positive advanced solid tumors (lung cancer and triple-negative breast cancer)
- Trial name
- NCT05341492
- Testing
- EGFR/B7H3 CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Pediatric Cancers, Solid Tumor Pediatric
Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.
- Trial name
- CMD03 (NCT06612645)
- Testing
- B7H3-IL7Ra CAR-T cells
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Chulalongkorn University
Ovary Neoplasm, Ovarian Cancer
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian…
- Conditions
- Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
- Trial name
- NCT06305299
- Testing
- iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly.
- Conditions
- Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Carcinoma
- Trial name
- NCT07509034
- Testing
- Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
This single-arm, single-center investigator-initiated trial (IIT) evaluates the safety, efficacy, and pharmacodynamic (PD)/pharmacokinetic (PK) profiles of CAR-T cells in patients with advanced solid tumors.
- Trial name
- NCT07152236
- Testing
- CAR-T
- Where
- China
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Osteosarcoma, Resection Margins
B7-H3 NIR Imaging for Osteosarcoma Surgery
Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and…
- Conditions
- Osteosarcoma, Resection Margins, B7-H3 Probe, Local Recurrence
- Trial name
- ROLN-B7-H3 (NCT06778603)
- Testing
- a targeted probe B7H3-IRDye800CW
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University People's Hospital
B7H3, CD276 Affibody
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors
Based on [68Ga]B7H3 Affibody-BCH, this study investigates its radioactive uptake and imaging capabilities in tumor patients, with the aim of establishing a correlation between radioactive uptake and B7-H3 receptor expression.
- Conditions
- B7H3, CD276 Affibody, PET/CT Imaing
- Trial name
- NCT06454955
- Testing
- [68Ga] B7H3 Affibody-BCH
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University Cancer Hospital & Institute
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage…
- Trial name
- NCT07892625
- Testing
- HS-20093 for Injection, ZG006, Adebrelimab Injection
- Volunteers
- 338 people
- Sponsor
- Hansoh BioMedical R&D Company